Profusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients

Reuters

Dec 15, 2025

Profusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients

Profusa Inc., a commercial stage digital health company, announced pilot phase data from a clinical study demonstrating that its Lumee oxygen tissue monitoring technology met the study's primary endpoints. The results were presented at the late breaking clinical trial session at the Paris Vascular Insights $(PVI)$ 2025 on December 13, 2025, in Paris, France. The study, conducted in the U.S., showed that Lumee oxygen tissue monitoring is a safe and effective method for long-term monitoring of peripheral artery disease (PAD) patients, with sensors remaining functional for up to one year and no sensor placement related adverse events reported. Profusa plans to begin commercialization of Lumee tissue oxygen monitoring in the European Union at the beginning of the second quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9601948-en) on December 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2591646669"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591646669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591646669?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591646669","market":"fut","top_or_hot":-1,"title":"Profusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Profusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PFSA\">Profusa Inc</a>., a commercial stage digital health company, announced pilot phase data from a clinical study demonstrating that its Lumee oxygen tissue monitoring technology met the study's primary endpoints. The results were presented at the late breaking clinical trial session at the Paris Vascular Insights <a href=\"https://laohu8.com/S/PVI\">$(PVI)$</a> 2025 on December 13, 2025, in Paris, France. The study, conducted in the U.S., showed that Lumee oxygen tissue monitoring is a safe and effective method for long-term monitoring of peripheral artery disease (PAD) patients, with sensors remaining functional for up to one year and no sensor placement related adverse events reported. Profusa plans to begin commercialization of Lumee tissue oxygen monitoring in the European Union at the beginning of the second quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9601948-en) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Profusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProfusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-15 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Profusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PFSA\">Profusa Inc</a>., a commercial stage digital health company, announced pilot phase data from a clinical study demonstrating that its Lumee oxygen tissue monitoring technology met the study's primary endpoints. The results were presented at the late breaking clinical trial session at the Paris Vascular Insights <a href=\"https://laohu8.com/S/PVI\">$(PVI)$</a> 2025 on December 13, 2025, in Paris, France. The study, conducted in the U.S., showed that Lumee oxygen tissue monitoring is a safe and effective method for long-term monitoring of peripheral artery disease (PAD) patients, with sensors remaining functional for up to one year and no sensor placement related adverse events reported. Profusa plans to begin commercialization of Lumee tissue oxygen monitoring in the European Union at the beginning of the second quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9601948-en) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014021.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL1hFhRL:1","article_id":"2591646669","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591646669","pubTimestamp":1765801811,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Profusa Inc., a commercial stage digital health company, announced pilot phase data from a clinical study demonstrating that its Lumee oxygen tissue monitoring technology met the study's primary endpoints. The results were presented at the late breaking clinical trial session at the Paris Vascular Insights  2025 on December 13, 2025, in Paris, France. The study, conducted in the U.S., showed that Lumee oxygen tissue monitoring is a safe and effective method for long-term monitoring of peripheral artery disease  patients, with sensors remaining functional for up to one year and no sensor placement related adverse events reported. Profusa plans to begin commercialization of Lumee tissue oxygen monitoring in the European Union at the beginning of the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4588":"碎股","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4082":"医疗保健设备","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","PFSA":"Profusa Inc","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Profusa报告PAD患者Lumee氧监测的积极试点数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PFSA":0.9},"content_text":"Profusa Reports Positive Pilot Data for Lumee Oxygen Monitoring in PAD Patients\n    \n\nProfusa Inc., a commercial stage digital health company, announced pilot phase data from a clinical study demonstrating that its Lumee oxygen tissue monitoring technology met the study's primary endpoints. The results were presented at the late breaking clinical trial session at the Paris Vascular Insights $(PVI)$ 2025 on December 13, 2025, in Paris, France. The study, conducted in the U.S., showed that Lumee oxygen tissue monitoring is a safe and effective method for long-term monitoring of peripheral artery disease (PAD) patients, with sensors remaining functional for up to one year and no sensor placement related adverse events reported. Profusa plans to begin commercialization of Lumee tissue oxygen monitoring in the European Union at the beginning of the second quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profusa Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9601948-en) on December 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}